RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia

4 Likes

This is great, but where’s the news on Iti-007? Intracellular were supposed to post an update after their meeting in late March.

1 Like

Sup edu…151515

1 Like

Perhaps it takes a little time to formulate a good update.

3 Likes

I don’t know much about economics but investment in their stock seems to be changing by the hour. How are people making these decisions without any information about whether of not they are going to send in the new drug application for lumateperone? Are they just guessing or is the information out somewhere. Maybe Intra-cellular’s silence means something, I would guess a no-go.

1 Like

People are just gambling at this point.

I’d give it a week or so. Someone in media relations or PR will write something, and then the higher ups probably all read it and send it back with revisions, and then they’ll go through the process again. They have to think about how what they say will affect their stock price. If the news is not great, likeliest time to release it is after 1pm pacific time on a Friday.

1 Like

Good update on the RP5063 though. (Which though this was a mouse study is in human trials already)

2 Likes

Its in phase 2…

2 Likes